In the latest trading session, Amgen (AMGN) closed at $344.55, marking a -1.17% move from the previous day. The stock fell short of the S&P 500, which registered a gain of 0.8% for the day. On the ...

Shares of Merck and Amgen are seeing declines Friday morning, dragging the Dow Jones Industrial Average into negative territory. The Dow was most recently trading 168 points, or 0.3%, lower, as shares ...

Biotech giant Amgen on April 22 announced the retirement of David Reese, executive vice president and chief technology officer, who has been with the Thousand Oaks-based company for 21 years. Reese, ...

Recent Federal Circuit decision draws a meaningful distinction between patents that claim a broad genus as the invention itself and those that claim ...

US biotech major Amgen has announced the retirement of David Reese, executive vice president and chief technology officer, ...

A former Amgen Inc. employee filed a proposed class action challenging the biotechnology company’s practice of charging ...

The fact that multiple Amgen Inc. ( NASDAQ:AMGN ) insiders offloaded a considerable amount of shares over the past ...

Lilly shares dipped, and Novo’s climbed, as Foundayo’s early trajectory diverged from that of oral Wegovy. Elsewhere, Regeneron inked a drug price deal and two companies announced leadership changes.

Amgen is scheduled to report its first-quarter results next week, and analysts expect a single-digit earnings dip.

Delve into the pipeline strategy of major biotech Amgen, which is increasingly diversifying its growth engines.

Amgen's Tepezza became the first drug approved by the FDA for thyroid eye disease (TED) in 2020, and the company is now looking to extend its role with a new, more patient-friendly formulation. The ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. New data from a mid-stage study of an Amgen obesity drug showed that it ...